Newsletter
June 1, 2012
- Kasznar Leonardos
Newsletter 2012.03 – The debate over ANVISA’s role in the examination of pharmaceutical patent applications continues
As you may be aware, due to article 229-C of the Brazilian IP Law, as amended by Law No. 10,196/01, whenever a patent application claims a pharmaceutical product or process, consent from the National Sanitary Surveillance Agency (ANVISA) is also required prior to granting the desired patent. This provision, however, has been the source of never-ending controversy and subject to growing attacks since it entered into effect in 2001.
The lack of statutory power of ANVISA to analyse patentability requirements of pharma applications was supported by the Attorney-General’s Office in legal opinions published in 2009 and 2011. Indeed, in their opinion, ANVISA should only make health-based assessments of applications sent for prior consent; prior consent should only be denied to applications in instances that granting the patents would pose health risks. How ANVISA would assess “health risks” on the basis of the information included in patent applications was left unanswered though.
Last related news
April 17, 2024
Anvisa opens its doors to Startups: Stepping towards Innovation in Medicines
Anvisa recently launched a public notice with the aim of selecting Startups involved in the research and development of medicines, in order … Anvisa opens its doors to Startups: Stepping towards Innovation in Medicines
April 11, 2024
Ministry of Finance Defines Regulatory Agenda for the Betting Market
In another step towards the realization and consolidation of the regulations provided for by the New Betting Law (Law 14.790/2023), the Ministry … Ministry of Finance Defines Regulatory Agenda for the Betting Market
March 21, 2024
European Union Artificial Intelligence Act is approved by the Parliament
On Wednesday (March 13th, 2024), the AI Act – European regulation that aims to lay down harmonized rules on artificial intelligence – … European Union Artificial Intelligence Act is approved by the Parliament